Insider Transactions in Q1 2025 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Scott N Boyle Chief Business Officer |
SELL
Open market or private sale
|
Direct |
669
-0.62%
|
$2,007
$3.15 P/Share
|
|
Feb 15
2025
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,370
-2.17%
|
$28,110
$3.18 P/Share
|
|
Feb 14
2025
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,368
-2.13%
|
$7,104
$3.18 P/Share
|
|
Feb 14
2025
|
Kelly Schick Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,500
+33.68%
|
-
|
|
Feb 14
2025
|
Mark Mossler Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,586
-8.01%
|
$4,758
$3.18 P/Share
|
|
Feb 14
2025
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,368
-2.14%
|
$7,104
$3.18 P/Share
|
|
Feb 14
2025
|
Scott N Boyle Chief Business Officer |
SELL
Open market or private sale
|
Direct |
490
-0.44%
|
$1,470
$3.15 P/Share
|
|
Feb 14
2025
|
Scott N Boyle Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,500
+33.66%
|
-
|
|
Feb 14
2025
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,914
-2.63%
|
$8,742
$3.18 P/Share
|
|
Feb 14
2025
|
Jolie Siegel Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,500
+33.76%
|
-
|
|
Feb 14
2025
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,847
-2.88%
|
$38,541
$3.18 P/Share
|
|
Feb 14
2025
|
Andrew Hirsch President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
223,500
+33.42%
|
-
|
|
Feb 14
2025
|
Leonard Reyno Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,145
-2.88%
|
$15,435
$3.18 P/Share
|
|
Feb 14
2025
|
Leonard Reyno Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,100
+32.74%
|
-
|
|
Feb 14
2025
|
Paige Mahaney Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,200
+21.17%
|
-
|
|
Feb 14
2025
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,559
-2.69%
|
$13,677
$3.18 P/Share
|
|
Feb 14
2025
|
Kendra Adams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,100
+33.92%
|
-
|
|
Feb 13
2025
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-3.07%
|
$5,205
$3.2 P/Share
|
|
Feb 13
2025
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-3.07%
|
$5,205
$3.2 P/Share
|
|
Feb 13
2025
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,135
-3.78%
|
$6,405
$3.2 P/Share
|
|
Feb 13
2025
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,863
-2.21%
|
$5,589
$3.2 P/Share
|
|
Jan 02
2025
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,074
+2.5%
|
$9,222
$3.66 P/Share
|
|
Jan 02
2025
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,757
+10.31%
|
$11,271
$3.66 P/Share
|